MITOLINE®-Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD).
Outdoor Holding Company Reports Fourth Quarter and Fiscal Year 2026 Financial Results
Atlanta, Ga., June 22, 2026 (GLOBE NEWSWIRE) — Outdoor Holding Company (Nasdaq: POWW, POWWP) (“OHC,” “we,” “us,” “our” or the “Company”), the owner of GunBroker.com, the largest online marketplace dedicated to firearms, hunting, shooting, and related products, today reported its financial results for its fourth fiscal quarter and year ended March 31, 2026.
Firm Capital Property Trust Announces Completion of Competition Bureau of Canada Inquiry Regarding Acquisition of 50% Interests in Ten Manufactured Home Communities for $218 Million
Expected Closing Set for Q3/2026
Expected Closing Set for Q3/2026
Chevron Strikes Power Deal With Microsoft for West Texas AI Data Center
The 2.7-gigawatt project will have its own on-site power plant fueled by Chevron’s local natural-gas production.
Kandi Technologies Accelerates Global Expansion
Kandi’s International Off-Road Vehicle Business Reaches Customers in 35 Countries and Regions, Expanding in Africa, Southeast Asia, Latin America and the Middle East Alongside Robust Momentum in the North American Market
EagleNXT Secures Order of eBee VISION ISR and eBee TAC Systems from Asia Pacific Customer
Two eBee VISION and three eBee TAC drones to support advanced ISR, tactical mapping, and operational readiness in the region
Country Stampede Breaks Attendance Records
Limited ticket inventory remaining
Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer’s Disease Biomarkers
NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, June 22, 2026 (GLOBE NEWSWIRE) — Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs. and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced a collaboration between DiamiR and AlzLabs Precision Diagnostics (“AlzLabs”) to generate protein and microRNA blood-based biomarker data with the focus on Alzheimer’s disease.
Notice: Australian Pokie Hub Highlights Upcoming Pokie Releases and Industry Trends
Sydney, New South Wales, AUSTRALIA, June 22, 2026 (GLOBE NEWSWIRE) —
Australian Pokie Hub has published an informational overview discussing upcoming pokie releases and emerging trends in online slot game development. The announcement outlines gameplay innovations, design trends, and features that players may encounter in future titles from established game studios.
Medical Affairs Outsourcing Market Size to Surpass USD 4.18 Billion by 2035 | SNS Insider
The U.S. Medical Affairs Outsourcing Market is projected to grow from USD 0.64 Billion in 2025 to USD 1.06 Billion by 2035, while Europe is expected to expand from USD 0.67 Billion to USD 2.41 Billion, supported by increasing clinical trial complexity, regulatory requirements, and pharmacovigilance outsourcing demand.
The U.S. Medical Affairs Outsourcing Market is projected to grow from USD 0.64 Billion in 2025 to USD 1.06 Billion by 2035, while Europe is expected to expand from USD 0.67 Billion to USD 2.41 Billion, supported by increasing clinical trial complexity, regulatory requirements, and pharmacovigilance outsourcing demand.
DEEP SEA MINERALS CORP. WELCOMES G7 LEADERS’ DECLARATION ON SECURING CRITICAL MINERALS SUPPLY CHAINS
Vancouver, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) — Deep Sea Minerals Corp. (CSE: SEAS) (OTCQB: DSEAF) (FSE: X450) (“Deep Sea Minerals” or the “Company“), a seabed mineral exploration and development company focused on advancing critical mineral opportunities from the deep ocean, today welcomed the G7 leaders’ declaration on securing supply chains for critical minerals, which underscores the strategic importance of diversified, transparent, and resilient critical minerals supply chains.
Quantum Cyber Issues Letter to Shareholders
Capitol Hill Meetings with Rep. McCormick and Senior Officials | Pentagon City Defense Conference | Connecticut Facility Purchase Agreement in Progress | Strong Financial Position
Capitol Hill Meetings with Rep. McCormick and Senior Officials | Pentagon City Defense Conference | Connecticut Facility Purchase Agreement in Progress | Strong Financial Position
Schouw & Co. share buy-back programme, week 25 2026
On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026.
CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies
SHENZHEN, CHINA, June 22, 2026 (GLOBE NEWSWIRE) — China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS”, or the “Group”) is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, the “Product”), a Class 1 therapeutic biological product has been approved by the National Medical Products Administration of the People’s Republic of China (“NMPA”) and the drug registration certificate was obtained on 22 June 2026. The Product is indicated for passive immunization in adults following rabies virus exposure.
CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies
SHENZHEN, CHINA, June 22, 2026 (GLOBE NEWSWIRE) — China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS”, or the “Group”) is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, the “Product”), a Class 1 therapeutic biological product has been approved by the National Medical Products Administration of the People’s Republic of China (“NMPA”) and the drug registration certificate was obtained on 22 June 2026. The Product is indicated for passive immunization in adults following rabies virus exposure.
AI Clinical Documentation Market Size to Reach USD 12.78 Billion by 2035 | SNS Insider
The U.S. AI Clinical Documentation Market is projected to grow from USD 0.41 Billion in 2025 to USD 3.96 Billion by 2035, while Europe is expected to reach USD 5.15 Billion from USD 0.42 Billion, supported by rising adoption of ambient AI, generative AI, and automated clinical documentation solutions across healthcare systems.
The U.S. AI Clinical Documentation Market is projected to grow from USD 0.41 Billion in 2025 to USD 3.96 Billion by 2035, while Europe is expected to reach USD 5.15 Billion from USD 0.42 Billion, supported by rising adoption of ambient AI, generative AI, and automated clinical documentation solutions across healthcare systems.
We Investigated Polymarket’s Deceptive Marketing Campaign. Here’s What We Found.
The promotion bolstered the perception that Polymarket lets users make fast and easy money.
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
Ramat-Gan, Israel, June 22, 2026 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the publication of a peer-reviewed scientific article demonstrating the broad therapeutic potential of its lead drug candidates, Piclidenoson and Namodenoson, across multiple major diseases.